Clinical Cancer Research, Vol 1, Issue 11 1413-1420, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression

H Friess, Y Yamanaka, MS Kobrin, DA Do, MW Buchler and M Korc
Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Biological Chemistry, University of California, Irvine, California 92717, USA.

The erbB-3 gene encodes a transmembrane protein that is related to the epidermal growth factor (EGF) receptor and erbB-2. We compared erbB-3 expression in the normal human pancreas, human pancreatic carcinomas, and cultured human pancreatic cancer cell lines. Northern blot analysis of total RNA revealed the anticipated 6.2-kb mRNA transcript in all 19 normal pancreatic samples. In 17 of 27 pancreatic cancers, there was a 6.7-fold increase (P < 0.001) in erbB-3 mRNA levels. Southern blot analysis did not reveal erbB-3 gene amplification. Four of six pancreatic cancer cell lines exhibited the 6.2-kb erbB-3 mRNA transcript, and all four cell lines coexpressed the epidermal growth factor receptor and erbB-2. Using a highly specific antibody, we determined that faint to moderate erbB-3 immunoreactivity was present in the ductal cells in the normal pancreas. In 47% (27/58) of the pancreatic cancers, there were many cancer cells with intense erbB-3 immunostaining. The presence of erbB-3 in the cancer cells was associated with advanced tumor stage and shorter survival postoperatively. These data indicate that a significant proportion of human pancreatic cancers overexpress erbB-3, and that erbB-3 may contribute to disease progression in this disorder.

This article has been cited by other articles:

				M. Reschke, D. Mihic-Probst, E. H. van der Horst, P. Knyazev, P. J. Wild, M. Hutterer, S. Meyer, R. Dummer, H. Moch, and A. Ullrich HER3 Is a Determinant for Poor Prognosis in Melanoma Clin. Cancer Res., August 15, 2008; 14(16): 5188 - 5197. [Abstract] [Full Text] [PDF]

				P. Ghaneh, E. Costello, and J. P Neoptolemos Biology and management of pancreatic cancer Gut, August 1, 2007; 56(8): 1134 - 1152. [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				Y. Zhang, S. Banerjee, Z. Wang, H. Xu, L. Zhang, R. Mohammad, A. Aboukameel, N. V. Adsay, M. Che, J. L. Abbruzzese, et al. Antitumor Activity of Epidermal Growth Factor Receptor-Related Protein Is Mediated by Inactivation of ErbB Receptors and Nuclear Factor-{kappa}B in Pancreatic Cancer Cancer Res., January 15, 2006; 66(2): 1025 - 1032. [Abstract] [Full Text] [PDF]

				S. M. Weber Histological and Molecular Markers for Pancreatic Adenocarcinoma: Can They Help Us Define Which Patients Should Receive It? Ann. Surg. Oncol., March 1, 2005; 12(3): 200 - 201. [Full Text] [PDF]

				K. S.R. Spencer, D. Graus-Porta, J. Leng, N. E. Hynes, and R. L. Klemke ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by ErbB Family Receptor Tyrosine Kinases J. Cell Biol., January 24, 2000; 148(2): 385 - 397. [Abstract] [Full Text] [PDF]

				H. FRIESS, X.-Z. GUO, B.-C. NAN, O. KLEEFF, and M. W. BUCHLER Growth Factors and Cytokines in Pancreatic Carcinogenesis Ann. N.Y. Acad. Sci., June 30, 1999; 880(1): 110 - 121. [Abstract] [Full Text] [PDF]